These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 16233989

  • 1. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
    Richardson A, Kaye SB.
    Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
    [Abstract] [Full Text] [Related]

  • 2. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B, Bachvarov D.
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [Abstract] [Full Text] [Related]

  • 3. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G.
    Cytogenet Genome Res; 2009 Jul; 125(1):8-18. PubMed ID: 19617691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS, Wu X, Follen M, Gershenson D.
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [Abstract] [Full Text] [Related]

  • 6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C.
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
    Cao MM, Zhang JR, Wang SM, Hu XG, Hu LJ.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [Abstract] [Full Text] [Related]

  • 17. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
    Appierto V, Villani MG, Cavadini E, Gariboldi M, De Cecco L, Pierotti MA, Lambert JR, Reid J, Tiberio P, Colombo N, Formelli F.
    Oncogene; 2007 Jun 07; 26(27):3952-62. PubMed ID: 17213814
    [Abstract] [Full Text] [Related]

  • 18. Molecular mechanisms of drug resistance.
    Longley DB, Johnston PG.
    J Pathol; 2005 Jan 07; 205(2):275-92. PubMed ID: 15641020
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.